Fucosylated Alpha-1-Antitrypsin and Ovarian Cancer
Author Information
Author(s): S. Thompson, D. Guthrie, G.A. Turner
Primary Institution: The Medical School, Newcastle upon Tyne
Hypothesis
Can modified fucosylation of alpha-1-antitrypsin predict unresponsiveness to chemotherapy in ovarian cancer patients?
Conclusion
Fucosylated alpha-1-antitrypsin levels can help differentiate between ovarian cancer patients who respond to chemotherapy and those who do not.
Supporting Evidence
- 75% of non-responders had higher F-AT levels in their second specimen compared to the first.
- 86% of responders had unchanged or lower F-AT levels in their second specimen.
- F-AT levels were low or undetectable in sera from healthy women.
Takeaway
Doctors found a special protein in the blood of women with ovarian cancer that can help tell if their treatment is working or not.
Methodology
Blood samples were taken from ovarian cancer patients and healthy women, and fucosylated alpha-1-antitrypsin levels were measured using SDS/electrophoresis and Western blotting.
Limitations
The study only included women with ovarian cancer and may not apply to other types of cancer.
Participant Demographics
29 women with ovarian cancer (median age 54, range 41-69) and 9 healthy women (median age 55, range 44-65).
Statistical Information
P-Value
0.05>P>0.002
Statistical Significance
0.05>P>0.002
Want to read the original?
Access the complete publication on the publisher's website